Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2018

View Archived Issues

7 Hills Pharma receives support from NIH to develop next-generation integrin activator

Luye cleared for phase I trials in China with LY-03012

Cytokinetics presents data from phase II study of reldesemtiv

Novel collaborative agreement to develop Nanotaxi-formulated DNA dengue vaccine

Missense mutations in GLIS1 gene are linked to malformation syndromes

Phase II dose of BAL-101553 defined in solid tumors trial

GSX2 gene identified as causative of basal ganglia agenesis

Moxetumomab pasudotox pivotal trial data in relapsed/refractory hairy cell leukemia reported

Loss-of-function mutation in TCF12 gene linked to autosomal dominant Kallmann syndrome

Aquinnah Pharmaceuticals obtains NINDS grant to develop ALS drugs

New phase II trial studies arimoclomol for Gaucher's disease

Atossa completes dosing in phase I study of topical endoxifen

Immune Design opens phase III study of CMB-305 for synovial sarcoma

FDA approves use of Cinryze to prevent angioedema attacks in pediatric patients with HAE

PATH and SD Biosensor partner on new diagnostic for G6PD deficiency in malaria

Kiyatec initiates 3D-PREDICT study with EV3D assay

Xalud initiates phase I trial of XT-150 for osteoarthritic pain

TG Therapeutics and Novimmune enter global agreement to develop and commercialize TG-1801

Insights into the orthosteric and allosteric action of C5aR antagonists to guide drug development

Teijin Pharma presents CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors

Amgen discovers apelin receptor agonists

MTHFD2 inhibitors identified at Daiichi Sankyo

Shanghai Meton Pharmaceutical patents NADP+ inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...